Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Expands use of Nociscan in groundbreaking trial with Roger Härtl, MD Broomfield, CO, May 05, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –  Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians […]

The post Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine first appeared on Prism Media Wire.